Кардиоваскулярная терапия и профилактика (Dec 2014)

CARDIOVASCULAR DISEASES REGISTRY (RECVAZA): DIAGNOSTICS, CONCOMITANT CARDIOVASCULAR PATHOLOGY, COMORBIDITIES AND TREATMENT IN THE REAL OUTPATIENT-POLYCLINIC PRACTICE

  • S. A. Boytsov,
  • M. M. Luk’yanov,
  • S. S. Yakushin,
  • S. Yu. Martsevich,
  • A. N. Vorobyov,
  • A. V. Zagrebelny,
  • K. G. Pereverzeva,
  • E. A. Pravkina,
  • A. D. Deev,
  • E. Yu. Andreenko,
  • A. I. Ershova,
  • A. N. Meshkov,
  • R. P. Myasnikov,
  • S. S. Serdyuk,
  • M. S. Kharlap,
  • E. V. Bazaeva,
  • A. N. Kozminsky,
  • K. A. Moseychuk,
  • E. N. Kudryashov

DOI
https://doi.org/10.15829/1728-8800-2014-6-3-8
Journal volume & issue
Vol. 13, no. 6
pp. 44 – 50

Abstract

Read online

Aim. To study the structure of concomitant cardiovascular and comobid pathology, risk factors in patients with arterial hypertension (AH), coronary heart disease (CHD), with congestive heart failure (CHF) and atrial fibrillation (AF), and to evaluate the quality of diagnostics and treatment in the conditions of real outpatient-polyclinic practice by the Registry in Ryazanskaya region – a RF region with high level of cardiovascular mortality.Material and methods. Into the outpatient-polyclinic registry RECVAZA (Registry of cardiovascular diseases) totally 3690 patients included with AH, CHD, with CHF, AF and their comorbidity, who admitted physicians’ offices in 3 outpatient institutions in Ryazan city: 1047 (28%) males and 2643 (72%) females, mean age 66,1±12,9 y.o.Results. The AHG diagnosis was mentioned in 3648 (98,9%) patients: CHD – in 2548 (69,1%), CHF – 2726 (73,9%), AF – 530 (14,4%). In 79,5% cases there was comorbidity. In general each one patient had 2,6 diagnoses of 4 analyzed. Myocardial infarction and brain stroke were in 11,4% and 9,5% patients’ anamnesis; diabetes – in 19,1%. The level of investigation of patients did not match the expected level with cardiologic pathology. There was non-sufficient amount of investigations and drugs prescribed, especially ACE inhibitors and angiotensine receptor blockers in CHF patients, statins in CHD, beta-blockers in patients with myocardial infarction, anticoagulants in AF, though they had indications. At the moment of Registry, a discount rate of drug price had 16,7% patinets vs. 33,1% in previous years (p<0,0001).Conclusion. RECVAZA results revealed in AH, CHD, CHF and AF patients high prevalence of cardiovascular comorbidity, non-sufficient risk factors evelauation nad accordance to national and international guidelines for treatment – important and real gap for diagnostics and treatment quality improvement in AH, CHD, CHF, AF anf their concomitance.

Keywords